Loading...
•
Mar 31, 2023
Esperion Q1 2023 Earnings Report
Esperion reported Q1 2023 financial results, with U.S. net product revenue growing approximately 27% Y/Y.
Key Takeaways
Esperion reported a 29% increase in total revenue to $24.3 million for Q1 2023, driven by a 27% increase in U.S. net product revenue and a 33% increase in collaboration revenue. The company highlighted the positive reception of the CLEAR Outcomes trial and strengthened its capital position with $56 million in financing. However, the company experienced a net loss of $61.7 million.
U.S. net product revenue grew approximately 27% year-over-year to $17.0 million.
Retail prescription equivalents grew 15% year-over-year.
New to brand prescriptions grew 56% quarter-over-quarter.
Strengthened capital position with $56 million in financing.
Revenue by Segment
Forward Guidance
The company still expects full year 2023 operating expenses to be approximately $225 million to $245 million, including $25 million in non-cash expenses related to stock compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...